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The application of hyperthermia to cancer treatment is studied
using a novel model arising from the fundamental principles of
flow, mass and heat transport in biological tissues. The model
is defined at the scale of the tumour microenvironment and an
advanced computational scheme called the embedded multiscale
method is adopted to solve the governing equations. More
precisely, this approach involves modelling capillaries as one-
dimensional channels carrying flow, and special mathematical
operators are used to model their interaction with the
surrounding tissue. The proposed computational scheme is
used to analyse hyperthermic treatment of cancer based
on systemically injected vascular magnetic nanoconstructs
carrying super-paramagnetic iron oxide nanoparticles. An
alternating magnetic field is used to excite the nanoconstructs
and generate localized heat within the tissue. The proposed
model is particularly adequate for this application, since it
has a unique capability of incorporating microvasculature
configurations based on physiological data combined with
coupled capillary flow, interstitial filtration and heat transfer.
A virtual tumour model is initialized and the spatio-temporal
distribution of nanoconstructs in the vascular network is
analysed. In particular, for a reference iron oxide concentration,
temperature maps of several different hypothesized treatments
are generated in the virtual tumour model. The observations
of the current study might in future guide the design of more
efficient treatments for cancer hyperthermia.
1. Introduction
Hyperthermia is an emerging therapeutic strategy for cancer
treatment. In this approach, the malignant tissue is subjected
2016 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.
 on October 10, 2016http://rsos.royalsocietypublishing.org/Downloaded from 
2rsos.royalsocietypublishing.org
R.Soc.opensci.3:160287
................................................
to a high temperature, falling in the range between 42◦C and 50◦C for a sufficiently long time. There
is evidence that high temperatures can damage and kill cancer cells. Tumour shrinkage has also been
observed as a consequence of this treatment [1–5]. Unlike conventional chemotherapy approaches,
it has been shown that localized hyperthermia causes minimum damage to healthy body tissues
[6]. Hyperthermia has mostly been used in combination with other methods of tumour treatment,
e.g. chemotherapy and radiation [7–9], showing a considerable decrease in the tumour
size [10,11].
Over the past decades, mathematical and computational modelling have significantly contributed
to the field of hyperthermia cancer treatment (HCT). A review of the modelling approaches to HCT
highlights an evolution from full-body or organ-scale lumped parameter models towards spatio-
temporal modelling approaches, based on partial differential equations solved by means of advanced
numerical schemes. In early studies, Jain and co-workers [12,13] presented basic lumped and distributed
mathematical frameworks to estimate the distribution of the temperature during hyperthermia in
healthy and neoplastic tissues of mammals. In [14], a domain-integral-equation technique was used
to solve for temperature distribution in a human pelvic tumour model under an electromagnetic field
stimulation. The numerical results highlighted the feasibility of an effective localized heating of the
tumour tissue. A power deposition model along with the bio-heat transfer equation was proposed
in [15] to elucidate the comparative, prospective, concurrent and retrospective modalities of thermal
dosimetry. The model was capable of handling scenarios with different environments and tissue thermal
properties to predict the spatio-temporal temperature distribution. The results revealed the significance
of mathematical modelling for clinical tumour hyperthermia treatment from planning to post-therapy
evaluation. A three-dimensional coupled finite-element model was developed in [16] to study the
temperature and power density distribution for interstitial tumour treatment. The authors discussed
the sensitivity of the temperature field induced by electromagnetic heating of the inserted thermal
seeds with respect to the configuration of the three-dimensional vessels in the tissue. However, modern
techniques of hyperthermia have improved the efficacy of treatment by using nanotechnology. This
treatment strategy has recently become popular since it provides localized and minimally invasive
tumour therapy [17].
Iron oxide nanoparticles (IONPs), gold-based nanoparticles (AuNPs) and carbon-based nanoparticles
(CNPs) have been successfully tested for the localized generation of heat upon exposure to external
energy fields. AuNPs and CNPs have been used in photothermal therapy of tumour tissues [1,18–20],
because of their potential to absorb near-infrared light. This favourable property of AuNPs has also been
studied in novel computational investigations of targeted tumour heating [21]. On the other hand, if
IONPs are exposed to an alternating magnetic field (AMF), heat is produced [22]. One advantage of
using IONPs is that magnetic resonance imaging (MRI) scanners can readily identify particles within the
body organs [23–25]. The most important physical parameter in hyperthermic treatment is the specific
absorption rate (SAR), which evaluates the amount of heat generated by applying exogenous energy
sources onto the nanoparticles. There has been considerable in vitro research on SAR characterization
[25–29]. For instance, a three-dimensional cell death model coupled with a heat transfer module was
employed in [30] to assess the time evolution and spatial distribution of injured malignant cells and
temperature field in human prostate tissue. The results of numerical simulations were then successfully
verified against the conducted experiments on various solutions containing gold nanorods which were
heated by near-infrared irradiation method.
The aim of this study is to compare the heating efficiency of different strategies for deliveringmagnetic
particles to a tumour. More specifically, two different types of nanoparticles are considered in this
study: small, 20 nm individual IONPs, which accumulate within the tumour tissue via the enhanced
permeability and retention (EPR) effect; and large, sub-micrometre vascular magnetic nanoconstructs
(VMNs) which accumulate within the tumour tissue by adhering firmly to the diseased vasculature.
Two models are be adopted to describe IONPs and VMNs, respectively, because these vectors interact
differently with the tissue. For the former, we use the model previously described by Nabil et
al. [31]. For the latter, we develop here a new model. The proposed model features the essential
characteristics to model nanoconstructs that actively interact with the vasculature, such as VMNs.
Capillary leakage is addressed via a two-way coupling between the capillary vessels and the surrounding
microenvironment, denoted as the interstitial volume. The solution of coupled flow and mass transport
equations on the vascular network and in the interstitial volume enables us to capture the spatio-
temporal distribution of nanoparticles. This information is essential for modelling heat generation,
which directly depends on particle distribution, as shown experimentally in [32]. It should be noted
that, as compared with the well-known and extensively used Pennes’ bioheat equation [33], the
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proposed computational framework represents a significant improvement in that it does not use
a lumped spatial averaged formulation to model the contribution of blood perfusion on the heat
transfer.
To describe these phenomena, we adopt the general approach to model flow, mass and heat
transfer in a biological tissue using the theory of porous media combined with a multiscale approach
that naturally fits to modelling microcirculation. The following references give an overview on
these topics: [34–37]. One of the most significant features of the model is the ability to incorporate
microvasculature configurations based on physiological data. This is made possible by an advanced
computational scheme called the embedded multiscale method developed in [38,39] and already used in
[40,41] for studying perfusion and drug delivery. More precisely, this approach involves modelling
capillaries as one-dimensional channels carrying flow. Special mathematical operators are used to
model the interaction of capillaries with the surrounding tissue. This approach falls within the general
framework of computational multiscale methods, which appear to be successful tools for a qualitative
prediction of the complex phenomena involved in nanomedicine (see [42–45] among many other
examples).
Our approach is complementary to other multiscale methods that lay down their roots on mixture
theory and mathematical homogenization (see [46–48] for some paradigmatic examples). Under the
assumption of scale separation and locally periodic microstructure, these methods aim at determining
the average properties of the macroscale (characterized by the whole tumour), in the asymptotic
limit where the ratio between micro and macro characteristic scales vanishes. Rather than seeing
these methods as competitors to the proposed approach, we think that they will complement each
other. Indeed, the embedded multiscale method may facilitate and speed up the solution of the unit
cell problems defined in the asymptotic homogenization approaches (see, for instance [48–50]). The
numerical solutions obtained in this way may be processed by means of suitable averaging operators
in order to evaluate the impact of microscale flow and transport parameters, as well as microvascular
configuration such as tortuosity, on the perfusion properties of the whole tumour.
2. Models and methods
We aim at studying flow in the capillary network coupled with interstitial filtration, see equation (2.1),
transport of particles described by equation (2.2), generation and transfer of heat modelled by
equation (2.5). As schematically described in figure 1, these are sequentially coupled phenomena, in the
sense that each of them is affected by the previous ones. As a result, they have to be solved in the order
they are presented here. These phenomena can be modelled by means of space–time dependent partial
differential equations, which can be efficiently solved using an advanced numerical technique called the
embedded multiscale method. This technique has been developed in [40,41] and has been adapted here to a
more general setting, encompassing heat transfer. In the interest of clarity, we have discussed each model
by using the following sections: assumptions, notation and governing equations, boundary and initial
conditions and model parameters.
The adopted computational geometry in the current study is exhibited in figure 1. This model
illustrates a tumour slab of R3230AC mammary carcinoma on a rat model, acquired in [51] and made
available to the public as a result of the Microcirculation Physiome Project [52]. The tumour slab
dimensions are 220× 208× 92× 10−5 m and it contains 105 different segments with radii spanning from
5.5× 10−6 m to 33.2× 10−6 m. However, taking into account of the radius variability in the mathematical
model introduces several technical difficulties, for example, in the enforcement of mass conservation
at each bifurcation of the network, which have not been addressed yet in the available computational
solver. For this reason, we adopt here a constant radius R= 7.64× 10−6 m that is the arithmetic average
of the individual radii of each segment. A generalization of the flowmodel to variable capillary radius is
presented in [53] and will be used in forthcoming studies.
The computational model is decomposed in the microvascular network and the surrounding
malignant interstitial tissue, Λ and Ω , respectively. It should be mentioned that the subscript v
(vascular) is used to represent all the variables defined on the capillaries while the variables of
the tumour tissue are labelled with t (tissue). Our simulation studies illustrate a protocol for HCT
where the host and consequently the tumour slab is infused with a solution of particles. The injected
particles enter the virtual tumour model through the inlets of the capillary network. These inlets
are represented by the specific points of the capillaries intersecting with the chosen faces of the
tumour slab.
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Figure 1. Sketch of the VMN-based hyperthermia process, split into different phases: (i) manufacturing of the particles, (ii) definition
of the delivery protocol, (iii) set-up of the FEM computational model (iv) simulation of the VMN spatio-temporal distribution and
(v) simulation of hyperthermia and study of the temperature maps.
2.1. Flow
2.1.1. Assumptions
The flow model includes two components, i.e. the microcirculation and the flow in the interstitial tissue.
These parts interact by means of coupling conditions at the interface. In fact, the microvascular wall is
considered to behave as a semipermeable membrane. Furthermore, the malignant interstitial volume is
assumed to act as an isotropic porous structure. The flow through the tumour interstitium is represented
by Darcy’s filtration law.
Microcirculation is characterized by low Womersley and Reynolds numbers [54–56]. In these
conditions, the general Navier–Stokes equations reduce to steady Stokes flow. Under additional
assumptions of (i) straight channels, (ii) rigid walls, (iii) constant radius, (iv) no-slip boundary conditions
for the velocity and (v) the absence of body forces such as gravity and inertial forces; Stokes flow
further simplifies to Poiseuille equations, namely (2.1e). As discussed in [55,57–59] using the Poiseuille
model considerably reduces the computational cost of the problem. However, we apply the model in
conditions where Poiseuille’s assumptions are not rigorously satisfied. In particular, transmural flow is
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allowed, but it must be small with respect to the axial velocity component. Furthermore, each vessel
branch does not have to be straight, but curvature must be small. Improvements of the current flow
model are in order: (i) for a better approximation of the extravasation effects; (ii) to relieve constraints
on small curvature and consequently allow to analyse configurations characterized by high tortuosity,
which plays an important role on the average hydraulic conductivity of tumours, as discussed in [50];
(iii) to improve the characterization of stresses on the wall, which in turn will affect particle adhesion.
The arc length coordinate along with each capillary segment is represented by the symbol s, while
λ denotes the reference vector that characterizes the segment orientation. Furthermore, the approach of
[60,61] is applied to model lymphatic drainage.
2.1.2. Notation and governing equations
The coupled mathematical model for microcirculation and flow in interstitial volume is to find the
pressure pt, pv and the velocity fields ut, uv such that the flow problem is
− ∇ ·
(
κ
µ
∇pt
)
+ LLFp
s
v
(pt − pL)− fb(p¯t, pv)δΛ = 0, in Ω , (2.1a)
ut =− κ
µ
∇pt, in Ω , (2.1b)
− πR
4
8µ
∂2pv
∂s2
+ fb(p¯t, pv)= 0, s ∈Λ, (2.1c)
fb(p¯t, pv)= 2πRLp((pv − p¯t)− σp(πpv − πpt )), in Λ, (2.1d)
uv =−R
2
8µ
∂pv
∂s
λ, s ∈Λ (2.1e)
and − κ
µ
∇pt · n= βb(pt − p0), on ∂Ω . (2.1f )
where p¯t represents an average of the interstitial pressure acting on the capillary surface, namely
p¯t(s)= 12πR
∫ 2π
0
pt(s, θ )Rdθ ,
θ being the angular coordinate on the cylindrical surface representing the capillary wall.
2.1.3. Boundary conditions
We have imposed a pressure gradient along the capillary vessels. Since both the inflow and outflow of
the capillary vessels are located on the outer edges of the slab, we enforced a known pressure pin on
two neighbour inlet sides. On the other hand, outlet pressure pout is assigned to the opposite faces. The
pressure drop between inlets and outlets is calibrated using the following simple approach. Given an
estimate of the average blood velocity in the capillary circulation, equal to 0.1mms−1 according to the
data provided by Intaglietta et al. [62], we use Poiseuille’s Law to calculate the corresponding pressure
drop. More precisely, we have applied a fictitious model consisting of a straight rigid pipe of length |Λ|
and radius R, to calculate the pressure drop pin − pout that corresponds to a velocity of 0.1mms−1 in the
pipe. We have imposed the Robin-type boundary conditions (2.1f) for the blood flow in the interstitial
volume. In this equation, p0 stands for the far field pressure value, while βb denotes an effective flow
conductivity accounting for the tissue layers surrounding the tumour slab.
2.1.4. Constitutive laws and parameters
Let Lp be the hydraulic permeability of the vessel wall (see table 1 for units and physiological values)
and let pv − p¯t be the pressure difference between the vessels and the interstitial volume. Because of
osmosis, the pressure drop across the capillary wall is affected by the difference in concentration of the
chemicals dissolved in blood, [63,64], which determine the oncotic pressure jump (πpv − πpt ) modulated
by the sieving coefficient σp. The oncotic pressure is defined as π =RgTc, where c is the concentration of
a given osmotic agent, Rg is the universal gas constant and T stands for the absolute temperature. The
coefficient σp accounts for the difference of a semipermeable membrane compared to the case of ideal
permeability (i.e. no resistance force on the molecules passing through the membrane). It spans from 0
to 1, where small values characterize ideal membranes, while larger values are typical of selective filters.
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Table 1. Parameters and data for mass and thermal transport.
symbol parameter units value source equation
µ blood viscosity kg (ms)−1 4× 10−3 [40] (2.1b)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lp capillary permeability (m2s) kg−1 10−10 [40] (2.1d)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LLFp
s
v
lymphatic permeability (mmHg hour)−1 0.5 [40] (2.1a)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dIONP diameter of IONP m 1× 10−8 [32] —
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dVMN diameter of VMN m 0.84343× 10−6 [65] (2.2c)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mIONP mass of IONP gr 8× 10−18 [32] —
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mVMN mass of VMN gr 5.6548× 10−13 [65] (2.4)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ρ tissue density kg mm−3 1060× 10−9 [32] (2.5a)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
γ tissue-specific heat capacity J kg−1 K−1 3470 [32,34] (2.5a)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
κ tissue thermal conductivity kg mm−1 K−1 0.51× 10−3 [32,34] (2.5a)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
βT heat exchange coefficient W mm−2 K−1 2× 10−5 [32] (2.5b)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tbl blood temperature K 273.15+37 [32] (2.5a)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SAR specific absorption rate W kg−1 1× 106 [32] (2.5c)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
— mass of Fe3O4 per VMN gr/# 2.51328× 10−13 [32] (2.4)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In healthy capillaries, proteins dissolved into the blood serum and in particular albumin are
responsible for most of the oncotic pressure, which can rise up to about 25mmHg. To model this
effect, we set πpv = 25, πpt = 0mmHg and σp ≃ 1, since proteins hardly leak through the capillary walls
as capillary fenestrations are small with respect to protein’s molecular radius. As a result, we obtain
σp(πpv − πpt )= 25mmHg (1mmHg = 133.322 Pa). Since albumin serum concentration is 5–10 times bigger
than the VMN systemic concentrations reached after injection, the oncotic effect generated by the injected
VMNs can be neglected. This is the scenario taken into account in the simulations presented in this
work. However, data reported in [66] show that in leaky tumour vasculature, the oncotic pressure may
be significantly lower than 25mmHg, because the ratio between the protein radius and the radius of the
capillary fenestrations decreases. This is modelled by assigning a smaller value to the sieving coefficient
σp, which can fall below 10−3, according to Jain et al. [66]. Then, the role of VMNs on osmosis may
become relevant. Indeed, it may happen that the radius of VMN in use will be comparable or larger
than the radius of the fenestrations in the capillary wall. In this case, VMNs may become the dominant
oncotic agent in the tumour vasculature. This other scenario is not considered in this work, but will be
the subject of future studies.
In order to model the capillary phenotype typically observed in tumours, we increase the magnitude
of their hydraulic permeability as in [60], such that the model will account for the well-known EPR
effect. To balance leakage of arterial capillaries, venous and the lymphatic systems absorb the fluid in
excess. For the sake of generality, we include lymphatic drainage in the model, although the lymphatic
system may be disfunctional in tumours. Following [60,61], we model them as a distributed sink term
in the interstitial volume. It is assumed that the volumetric flow rate due to lymphatic vessels, ΦLF, is
proportional to the pressure difference between the interstitium and the lymphatics, namely ΦLF(pt)=
LLFp
s
v (pt − pL), where LLFp is the hydraulic permeability of the lymphatic wall, s/v is the surface area of
lymphatic vessels per unit volume of tissue and pL is the hydrostatic pressure within the lymphatic
channels. In [31], the role of capillary permeability and lymphatics on small particle (nanometre size)
distribution and hyperthermia has been thoroughly analysed, with the conclusion that the former
parameter plays a dominant role. Here, the same conclusion is strengthened by the fact that VMN
(micrometre size) constructs do not extravasate in the time scale of interest.
2.2. Mass transport model
The mass transport model governs the distribution of (micrometre size) nanoconstructs (VMN) within
the microvascular network. Iron oxide is delivered by loading it into VMNs (see figure 1 for a sketch
of the process). The symbol cv denotes the mass concentration of iron oxide (mass/volume) in the
vasculature.
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2.2.1. Assumptions
VMNs are functionalized particles able to bind to (inflammatory) receptors on the capillary walls. We
assume that the particle size (≃800 nm for the simulations considered here) is on average larger than
the transvascular gap size, which is estimated to range between 200 and 1200 nm according to Hobbs
et al. [67], in various types of tumours. As a result, VMNs do not extravasate, but they usually circulate
for several hours in the systemic vasculature before being metabolized. Furthermore, it is assumed that
injecting VMNs into the circulation does not alter the blood properties. We also posit that VMNs are
not damaged during circulation and that they do not release any sub-products. Then, we assume that a
fixed constant concentration of VMNs is available in the vasculature for a fixed period of time. This time
window is the one that matters for HCT and it will be called from now on the circulation time. We will
consider various computational experiments characterized by different circulation times.
The adhesion of VMNs to the capillary walls is described following the lines of [65,68,69]. More
precisely, at each point of the vascular tree, we define a vascular adhesion rateΠ (s) that directly depends
on the particle size and inversely depends on the particle drag force induced by blood flow, as described
in the formula for the probability of adhesion, Pa, reported below. The density of iron oxide on the
vascular walls, Ψ (s, t), is determined by the combination of the particle concentration (in terms of iron
oxide mass per volume, cv) with the vascular adhesion rate.
2.2.2. Notation and governing equations
We denote by cv the concentration of iron oxide carried by VMNs. The concentration cv is governed by
the following equations:
∂cv
∂t
+ ∂
∂s
(
(uv · λ)cv −Dv ∂cv
∂s
)
+ 2πR
πR2
Πcv = 0, in Λ× (0, t), (2.2a)
Pa =mlK0aα2πr20 exp
(
−βµ|WSR|
α2
)
, (2.2b)
Π =Pa|WSR|d
VMN
2
(2.2c)
and Ψ (s, t)=
∫ t
0
Πcv(s, τ ) dτ . (2.2d)
The system of equations (2.2) is complemented by the definition of the mean iron oxide concentration in
the tumour slab
cref = |Ω|−1
∫
Λ
(2πRΨ + πR2cv). (2.3)
2.2.3. Boundary and initial conditions
Given a desired mean concentration, cref, we determine the constant systemic concentration, cinj, that is
necessary to match the targeted cref at a time equal to the particle circulation time. The concentration cinj
measures the mass of iron oxide per unit volume of blood, and it is the value that we enforce at the inlets
of the virtual tumour slab, in order to make (2.2) solvable. The method for calculating cinj on the basis of
cref will be discussed later on. Once cinj has been found, we also determine how many VMNs should be
injected to guarantee this iron oxide concentration, that is ρinj. This calculation is performed by means of
the following conversion formula:
cinj = ρinj ×mass of iron oxide per VMN. (2.4)
2.2.4. Model parameters
For VMN delivery, particle density is assumed to be equal to the density of water. The value of VMN
vascular deposition parameter Π = 3× 10−9 m s−1 is calculated on the basis of constants α2 = 4× 109
#/m2, β = 2.3× 1011 N−1 and mlK0ar20 = 1.26× 10−9 m2, which come from [65], and an average wall
shear rate |WSR| = 50 s−1. This wall shear rate value is consistent with the Poiseuille flowmodel, namely
|WSR| = 4uv/R, using an average blood velocity in the network of 0.1mms−1 and the capillary radius
of R= 7.64 × 10−6 m. The extension of the model to variable wall shear rate and vascular adhesion
parameter will be addressed together with one for variable capillary radius presented in [53].
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2.3. Heat transfer model
2.3.1. Assumptions
According to the general framework proposed in [36], heat transfer in a biological tissue is governed
by thermal conduction and convection in the tissue matrix, blood-tissue heat exchange, exogenous heat
generation and heat flux through the domain boundaries. As thoroughly studied in [32], heat is generated
upon irradiation of iron oxide with exposure to a low-frequency alternating magnetic field (AMF). This
phenomenon is defined through a source term, i.e. fT(cv), of the heat transfer equation in the tumour
slab. Low-frequency AMF is desirable because it avoids non-specific thermal generation [31,32] due to
excitation of the electrolytes dissolved in the interstitial fluid or to other mechanisms [34]. Considering
that in our model heat generation takes place in a small portion of the host body, it is also reasonable to
postulate blood temperature homeostasis. Therefore, blood temperature Tbl is assumed to be constant.
2.3.2. Notation and governing equations
We investigate the distribution of temperature field (T) within the tumour tissue. Based on the
aforementioned assumptions, temperature is modelled using the following set of relations. These
equations include convection and diffusion of heat through interstitial flow, Tut − (κ/ργ )∇T, as well
as heat sink by blood flow, 2πRβT(T − Tbl), lymphatic drainage, LLFp (s/v)(pt − pL)(T − Tbl), and also heat
loss from the outer boundaries of the tumour slab, βT(T − Tbl),
ργ
[
∂T
∂t
+ ∇ ·
(
Tut − κ
ργ
∇T
)
+ LLFp
s
v
(pt − pL)(T − Tbl)
]
+ 2πRβT(T − Tbl)δΛ = fT(cv), in Ω × (0, t), (2.5a)
(−κ∇T + ργTut) · n= βT(T − Tbl), on ∂Ω × (0, t) (2.5b)
and fT(cv)= SAR(2πRΨ + πR2cv)δΛ. (2.5c)
2.3.3. Boundary and initial conditions
We have imposed Robin-type boundary conditions in order to account for heat transfer over the
external boundaries of the slab using equation (2.5b). In this expression, βT denotes an effective
thermal conductivity considering the surrounding tissue layers around the tumour tissue. Initially, the
temperature of the entire tumour slab is assigned to be equal to the reference blood temperature Tbl.
2.3.4. Constitutive laws and parameters
For the simulations, we have used model parameters reported in table 1. The thermo-physical properties
of the tissue, i.e. density, specific heat capacity and thermal conductivity, all come from [32], as well as
the values of blood temperature, size and specific absorption rate (SAR) of magnetic nanoparticles.
2.4. Computational solver
The finite-element method (FEM) is employed to discretize the system of equations (2.1), (2.2) and (2.5).
Upon dividing the tumour interstitium and the capillary vessels domains, Ω and Λ, respectively, into
tiny elements (as shown in figure 1), piecewise polynomial functions are adopted to approximate the
solution of the governing equations formulated in their weak (or variational) form.
We notice that computational domainsΩ andΛ are dimensionally heterogeneous. The tumour tissue
is three-dimensional, whereas the capillaries are one-dimensional. The numerical scheme is based on
the idea of representing the capillaries as a network of one-dimensional channels acting as concentrated
sources of flow and heat, immersed into the interstitial volume. As a result, it can be classified as an
embedded multiscale method.
The superior feature of the employed numerical scheme is the full independence of computational
grids used to approximate the equations on the vessels and in the interstitial tissue. Therefore, any
arbitrary and complex capillary network geometry can be potentially used as a test case. The theoretical
features of this numerical approximation method have been extensively discussed by D’Angelo [38,39].
For the implementation of these algorithms, we have used GetFEM++, an open source finite-element
library of C++ [70]. We have adopted the generalized minimal residual (GMRES) method along with
incomplete-LU preconditioning in order to solve the system of discretized algebraic governing equations.
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The computational domain consists of 49 655 grid points and 272 872 tetrahedral elements, which is
sufficient to reach the independence of the numerical results from the discretization. In fact, by examining
the effect of mesh size on the simulation results, the results are insensitive to the numerical grids beyond
257 109 elements. More details of the numerical scheme are presented in [40,41].
Numerical simulations have been performed on a standard single core desktop PC. The clock time
for simulations is comparable to the simulated time (i.e. a simulation that ends at 12 h requires 12 h of
computational time). We believe that these figures feature significant margins of improvement, as the
ongoing optimization of the computational efficiency of the software actually shows.
3. Results and discussion
3.1. Protocols for simulated experiments
We recall that IONPs (≃20 nm in size) are generally characterized by a short longevity in the circulation
and the mechanism of accumulation within the neoplastic tissue is mostly via passive extravasation
across the tumour fenestrations, following the well-known EPR effect [68,71]. On the contrary, VMNs
are designed to circulate for longer times (up to 48 h post systemic injection) and, most importantly, to
adhere on the tumour vasculature rather than passively extravasating [72].
Four different circulation times are considered for the injected nanoparticles, namely 40min (short-
term circulation); 12, 24 and 48 h (long-term circulation). The 40min case is specifically considered
for the short-lived IONPs, whereas the longer circulation times are for the VMNs. In all simulations,
HCT is obtained via an external AMF, which is continuously applied only for the last 20min of
nanoparticle circulation. The average concentration of magnetic material in the tumour slab, denoted as
cref, previously introduced together with system (2.2), is one of the main factors controlling the efficacy
of HCT. In particular, cref is fixed to be 1mgml−1 (1mgml−1 = 1 kgm−3) in all simulations, in that
it matches the particle concentrations used in the experiments of Cervadoro et al. [32]. The injected
concentration, cinj, was selected to match a desired amount of magnetic material in the system, cref,
for each given value of the nanoparticle circulation. The values of cinj required to match the target
value of cref = 1mgml−1 at the final time for all the simulation cases are listed in the first column of
table 2. These numbers are calculated using the numerical simulations. More precisely, based on equation
(2.2d), there should be an inverse relationship between the nanoparticle circulation time and the injected
concentration of nanoparticles necessary to achieve the reference concentration of cref = 1mgml−1 in the
tumour. Specifically, Ψ (s, t)=Π (s)cv(s)t, where Ψ is related to the target cref = 1mgml−1. Furthermore,
if cv and Π are almost uniform in space, cv(s)= cv, Π (s)=Π , it is also obtained cref = (2πRΠcvt+
πR2cv)|Λ|. Using this equation, approximate estimates of the systemic concentration required to match
cref are determined. After performing the simulation for each test case, we have adjusted the dosage, cinj,
such that the desired final VMN concentration within the slab is achieved, which then resulted in the
data of table 2.
3.2. Description of the results
Employing the previously described computational model, the following analyses have been carried out:
(i) Quantifying the distribution of nanoparticles within the tumour as a function of the circulation
times, namely 40min, 12, 24 and 48 h. The results are presented in figure 2. In particular, figure 2a
presents the nanoparticle concentration in the blood flow (cv), and figure 2b presents the density
of nanoparticles adhering to the vessel walls (Ψ ). All the cases have the same cref = 1mgml−1 at
the final simulation time, which corresponds with the circulation time.
(ii) Analysis of the temperature maps associated with the AMF stimulation of VMNs as a function
of the circulation times, namely 40min, 12, 24 and 48 h. For all the tested cases, the tumour slab
is exposed to an AMF only for 20min of the circulation period. The results are shown in figure 3.
(iii) Comparison of temperature maps within the tumour slab for treatments with IONPs and VMN
for a 48 h circulation time. We recall that for IONPs we do not adopt the mass transport model
(2.2), but the specific model for small particles already developed in a companion study [31]. In
particular, the model for IONP differs from (2.2) because it incorporates particle extravasation,
diffusion and transport in the interstitial space. The temperature maps are presented in figure 4.
The top panel is for the IONPs, whereas the lower panel is for VMNs.
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cv (mg ml–1)
342.8
12 h
24 h 48 h
24 h 48 h
40 min 12 h
281.15
219.5
157.85
96.2
cv (mg ml–1)
28.7
28.645
28.56
28.476
28.36
7.24
7.2262
7.2091
7.192
7.172
cv (mg ml–1)
y (1 cm–2)
1.07296 × 109
8.048 × 108
5.366 × 108
2.684 × 108
214297
y (1 cm–2)
1.6297 × 109
1.222 × 109
8.147 × 108
4.073 × 108
331328
y (1 cm–2)
1.63466 × 109
1.226 × 109
8.172 × 108
4.086 × 108
332549
y (1 cm–2)
1.6197 × 109
1.215 × 109
8.097 × 108
4.048 × 108
328874
cv (mg ml–1)
14.44
14.417
14.383
14.349
14.3
(b)
(a)
Figure 2. Particle concentration in the bloodflow, cv, (a) and concentration of particles adhering to the capillarywalls,Ψ , (b) for 40min,
12 h, 24 h and 48 h of VMNs circulation time.
Table 2. Required VMN systemic concentrations, cinj, for reaching cref = 1mgml−1 using different particle circulation times.
circ. time cinj (kg m−3) % of cv in cref % ofΨ in cref
40min 342.8 44.87 55.13
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12 h 28.7 3.76 96.24
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24 h 14.44 1.89 98.11
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
48 h 7.24 0.95 99.05
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Figure 3. Maps of temperature increase above 37◦C for 40min, 12 h, 24 h and 48 h of VMNs particle circulation time.
3.3. Particle distribution and concentration maps
In figure 2, the volumetric concentration of nanoparticles within blood (cv) and the surface density of
nanoparticles adhering to the capillaries (Ψ ) are plotted for different circulation times. Indeed, in order
to have the same cref = 1mgml−1 at the final time point, the shorter is the circulation time, the larger
have to be the injected concentration of nanoparticles, cinj, and the volumetric concentration in blood, cv.
This is shown in figure 2awhere cv steadily decreases as the circulation time increases. Note also that the
spatial distribution of cv along the vasculature is not affected by the circulation times (figure 2a), implying
a direct scaling between vascular concentrations and circulation times. Conversely, the surface density
of adhering nanoparticles grows moderately as the circulation time increases, as shown in figure 2b.
The most significant finding is that a very large VMNs injection concentration is required to achieve the
target of cref = 1mgml−1 when the short-term protocol is adopted. This delivery approach is obviously
inefficient, as it does not exploit the persistence of VMNs in the circulation. By contrast, long-term
delivery protocols feature much better performances, because the same target is reached with lower
concentrations of injected VMNs.
Quantitative data on the volumetric concentrations and surface density of nanoparticles are provided
in the third and fourth columns of table 2. The contribution of Ψ and cv to the value of cref = (2πRΠcvt+
πR2cv)|Λ| at the end of circulation period is studied. As the circulation time increases, the role of cv
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Figure 4. Maps of temperature increase above 37◦C for IONPs injection for 40min studied in [31] compared with VMN delivery and
circulation for 48 h.
becomes almost negligible compared with Ψ . In other words, for long particle circulation time, particle-
to-wall interaction (adhesion) is the main driving force for nanoparticle accumulation within the slab.
Furthermore, figure 2a shows that for long nanoparticle circulation time, the vascular concentration
of nanoparticles, cv, is almost uniform. For this reason, the approximate relation cref ≃ 2πRΠcinjt is
accurate and as a result the systemic concentration, cinj, turns out to be inversely proportional to the
particle circulation time. As a result, the most effective case is the 48 h, which features the longest
duration.
3.4. Temperature maps
Temperature distribution maps are presented in figure 3. As previously mentioned, for all tested cases,
the AMF exposure and in turn heat generation in the tumour tissue occurred within the last 20min of
the circulation time. First, it can be observed that temperature maps are similar in that the reference
concentration of magnetic material is fixed to be cref = 1mgml−1 for all cases. In the case of 40min, the
maximum temperature reached in the slab is of 11.34◦C, while for longer times it goes up to 12.03◦C,
only 6% higher than in the previous case.
3.5. Comparison of temperature maps for iron oxide nanoparticle and vascular magnetic
nanoconstruct injection
In figure 4, the temperature distributionwithin the tumour slab for IONPs (40min circulation) andVMNs
with 48 h of circulation time are compared. In both cases, the reference concentration of cref = 1mgml−1
in the tumour slab is reached at the end of the circulation time. Similar systemic concentrations cinj are
also used in these protocols. In the VMN case, table 2 shows that cinj = 7.24 kgm−3 of magnetic material
is used in the systemic circulation, while in [31] cinj = 6.94 kgm−3 of magnetic material were used for the
simulations of IONPs in the same conditions. These data show that these two simulation protocols are
almost equivalent in terms of input conditions.
For IONPs, figure 4 confirms the findings of Nabil et al. [31], where it is shown that for tumour
slabs sufficiently large, an inhomogeneous particle distribution and temperature fields are generated.
More precisely, a definite temperature gradient is observed, from the inflow to the outflow sections
of the vasculature. The results reported in figure 4 for VMN show that this delivery method lowers
the temperature heterogeneity in the tumour tissue. In particular, a uniform level of hyperthermia is
obtained in the slab, with the highest value of temperature increase in the middle of the region of
interest, where heat loss is lower compared with the tissue boundaries and the density of capillaries is
higher. In conclusion, provided that the capillary network is evenly perfusing the tumour, VMN delivery
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guarantees uniform hyperthermia levels, rather insensitive to the direction of the microcirculation and
interstitial flow.
4. Conclusion
A new mathematical model has been developed to investigate the coupled heat and mass transfer at the
level of tumour microenvironment. Basic balance and constitutive laws have been adopted to simulate
the interactions among the main compartments of the tumour tissue. The main contribution of the
computational framework is that flow and heat transfer in the capillary and interstitial medium are
coupled for simulations performed using a microvasculature configuration based on physiological data.
The simulations suggest that network topology and particle distribution along the microvasculature
are the key factors in VMN delivery approach, because they affect the temperature field within the
tumour tissue. Since VMN extravasation is unlikely, we observe that the density of particles decorating
the arterial wall is directly proportional to time. This suggests that efficient delivery protocols for VMN
should allow for a significant time lag between particle injection and exposure to the alternatingmagnetic
field and consequent heating.
Finally, a comparison has been made between the 48 h VMN delivery protocol, and the case of
40min bolus injection of iron oxide nanocrystals (IONPs). These two cases are quite similar in terms
of the required injection dosage of IONPs. However, different mechanisms governing these two injection
approaches result in distinct behaviours of temperature increase and different temperature distributions
within the slab. In particular, for the IONP injection method, a clear temperature gradient within the slab
was observed with the higher temperature occurring at the inflow section of the slab. In contrast to the
IONP injection approach, the mechanisms governing VMN delivery is such that interstitial blood flow
andmicrocirculation barely affect the level of hyperthermia. In fact, the key parameter for VMN delivery
is the topology of the microvasculature. Since the capillaries spread rather uniformly within the tumour
slab, a nearly constant hyperthermia level is obtained throughout the tissue.
Although the novel mathematical model provides a better understanding of the mechanisms
governing tumour hyperthermia, there is still room for further improvements. For example, as
previously remarked, the assumptions at the basis of Poiseuille equation are quite restrictive and they do
not completely fit to microcirculation. A more detailed asymptotic analysis of Navier–Stokes equations
in the limit of low Reynolds numbers may inform about better approximations of flow in highly tortuous
and leaky channels. For mass transport, the contribution of VMNs to oncotic pressure gradients, which
may affect the fluid balance between the vascular and interstitial compartments, should be carefully
investigated. From a more general perspective, we envision two concurrent directions of development.
One arises observing that in the present approach the virtual tumour model is isolated. In fact, the
proposed model does not account for all the possible interactions of the malignant tissue with the
surrounding microenvironment. It also does not take into account the role of tissue metabolism on the
final delivered dosage of IONPs and consequently on the level of hyperthermia. Coupling the current
model with other ones that account for the mass and heat metabolism at the systemic level will be a
future direction of improvement. In particular, wewill consider extensions of themodel where the VMNs
systemic concentration enforced at the endpoints of the vasculature, as well as their circulation time, are
not constant but progressively decrease due to particle sequestration into surrounding organs.
The second limitation consists in the difficulty of determining the model coefficients. In particular, the
interaction of VMN with the vascular wall is modelled here through the vascular adhesion parameter,
which describes the macroscopic effect of many complex phenomena. A more advanced approach,
currently under development, is the combination of the mass and heat transport models with accurate
microscale simulations for the interplay of a single particle with blood flow and the arterial wall.
In conclusion, the present model, which addresses tumour hyperthermia through a mesoscale
approach, will surely benefit from integration with macro- and micro-scale complementary models, in a
comprehensive multi-scale description of VMN transport and heat generation.
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